Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09TYM
|
||||
| Former ID |
DNC004402
|
||||
| Drug Name |
LEUKOTRIENE_B4
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H32O4
|
||||
| Canonical SMILES |
CCCCCC=CCC(C=CC=CC=CC(CCCC(=O)O)O)O
|
||||
| InChI |
1S/C20H32O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18-19,21-22H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7+,9-6-,14-10+,15-11-/t18-,19-/m1/s1
|
||||
| InChIKey |
VNYSSYRCGWBHLG-AMOLWHMGSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Leukotriene B4 receptor 2 | Target Info | Inhibitor | [2] | |
| Leukotriene B4 receptor 1 | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | |||||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| PANTHER Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | ||||
| Reactome | Leukotriene receptors | ||||
| G alpha (q) signalling eventsR-HSA-391906:Leukotriene receptors | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP80:Nucleotide GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Spinal Cord Injury | |||||
| References | |||||
| REF 1 | Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994). | ||||
| REF 2 | Diaryl ether/carboxylic acid derivatives of LY255283: Receptor antagonists of leukotriene B4, Bioorg. Med. Chem. Lett. 3(10):1985-1990 (1993). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.